Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sens. McCain, Schumer Sponsor Generic Drug Approval Acceleration Bill

This article was originally published in The Tan Sheet

Executive Summary

Sens. John McCain (R-Ariz.) and Charles Schumer (D-N.Y.) intend to rally support in the next session of Congress for legislation introduced Sept. 14 that would ease the FDA approval process for generic drugs.
Advertisement

Related Content

McCain/Schumer Generic Drug Bill Would End 30-Month Stay Of Approval
McCain/Schumer Generic Drug Bill Would End 30-Month Stay Of Approval
McCain/Schumer Generic Drug Bill Would End 30-Month Stay Of Approval
Generic Exclusivity Usefulness Needs Review, FDA's Dickinson Says
Generic Exclusivity Usefulness Needs Review, FDA's Dickinson Says
Generic Exclusivity Usefulness Needs Review, FDA's Dickinson Says
FTC Generic Drug Survey To Gather Information On Late-Listed Patents
FTC Generic Drug Survey To Gather Information On Late-Listed Patents
FTC Generic Drug Survey To Gather Information On Late-Listed Patents
GPhA Still Wary Of Generic User Fees; Issue Tied To Waxman/Hatch Reform

Topics

Advertisement
UsernamePublicRestriction

Register

PS091670

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel